| Summary: | Cellular mesenchymal–epithelial transition factor (c-Met), an oncogenic transmembrane receptor tyrosine kinase (RTK), plays an essential role in cell proliferation during embryo development and liver regeneration. Thioredoxin reductase (TrxR) is overexpressed and constitutively active in most tumors closely related to cancer recurrence. Multi-target-directed ligands (MTDLs) strategy provides a logical approach to drug combinations and would adequately address the pathological complexity of cancer. In this work, we designed and synthesized a series of selenium-containing tepotinib derivatives by means of selenium-based bioisosteric modifications and evaluated their antiproliferative activity. Most of these selenium-containing hybrids exhibited potent dual inhibitory activity toward c-Met and TrxR. Among them, compound <b>8b</b> was the most active, with an IC<sub>50</sub> value of 10 nM against MHCC97H cells. Studies on the mechanism of action revealed that compound <b>8b</b> triggered cell cycle arrest at the G<sub>1</sub> phase and caused ROS accumulations by targeting TrxR, and these effects eventually led to cell apoptosis. These findings strongly suggest that compound <b>8b</b> serves as a dual inhibitor of c-Met and TrxR, warranting further exploitation for cancer therapy.
|
|---|